|View printer-friendly version|
Details of the session and poster discussion are as follows:
|Session:||110 - THE FUTURE OF LUNG CANCER BIOMARKERS: WHERE SHOULD WE LOOK?|
|RAPiD: Rapid Abstract Poster Discussion Session|
|Day and time:||Tuesday, May 21, 2019 - 2:15 - 4:15 PM EDT|
|Location:||Arena (Level 2), KBHCCD|
|Poster Title:||Blinded Prospective Validation Study of a Whole Blood Gene-Expression Classifier for the Diagnosis of Benign Versus Malignant Pulmonary Nodules|
|Viewing Time:||2:15-2:45 PM EDT|
|Discussion Time:||2:45-4:15 PM EDT|
The abstract can be viewed here.
DetermaVu™ is being developed as an intermediate step to confirm the absence of cancer between imaging modalities (LDCTs) detecting suspicious lung nodules and downstream invasive procedures that determine if the nodules are malignant.
DetermaVu™ is a trademark of
OncoCyte Forward Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are forward-looking statements. These statements include those pertaining to the implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for
LifeSci Advisors, LLC
LifeSci Public Relations